A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.

NCT Number	NCT07091019
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Chronic Myelogenous Leukemia - Chronic Phase
Enrollment	1,000 participants
Start Date	2025-12-17
Primary Completion	2033-04-20 (estimated)
Study Completion	2033-04-20 (estimated)
Updated on ClinicalTrials.gov	2026-07-20